Omnicell’s $225 Million Acquisition Of 340B Link Business From PSG


Sidley Austin LLP advised Omnicell, Inc. on the deal.

Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, has entered into a definitive agreement with Pharmaceutical Strategies Group (PSG) to acquire its 340B Link business for total aggregate cash consideration of $225 million, subject to customary adjustments. The acquisition will add a comprehensive and differentiated suite of software-enabled services and solutions used by certain eligible hospitals, health systems, clinics, and entities to manage compliance and capture 340B drug cost savings on outpatient prescriptions filled through the eligible entity’s pharmacy or a contracted pharmacy partner.

Sidley deal team was led by Jennifer Fitchen (Picture), Feifei Bian, Edwin Norris, Corey Perry, Daniel Ray and Stephen Fronk.

Involved fees earner: Feifei Bian – Sidley Austin LLP; Jennifer Fitchen – Sidley Austin LLP; Stephen Fronk – Sidley Austin LLP; Edwin Norris – Sidley Austin LLP; Corey Perry – Sidley Austin LLP; Daniel Ray – Sidley Austin LLP;

Law Firms: Sidley Austin LLP;

Clients: Omnicell, Inc.;

Author: Ambrogio Visconti